EU HTA Goes Live: What the JCA Means for Access, Pricing & IRP

On 12 January 2025, the EU Health Technology Assessment Regulation moved from preparation into operation. New oncology medicines and advanced therapy medicinal products entering scope are now subject to Joint Clinical Assessment (JCA) at European level.

The JCA does not create a single European reimbursement decision or price. National authorities retain responsibility for appraisal, economic evaluation, reimbursement and pricing. Nevertheless, a shared European assessment of relative clinical effectiveness changes the evidence environment in which those national decisions are made.

One clinical evidence package, many national decisions

The attraction of JCA is greater consistency and less duplication in the clinical assessment of new technologies. For manufacturers, however, it also means that evidence strategy must anticipate the needs of multiple Member States earlier in development.

Differences in national comparators, treatment pathways and patient populations do not disappear. The challenge is to build an evidence package robust enough to support a joint assessment while still being adaptable to country-specific economic and reimbursement questions.

Pricing remains national — but timing may become more connected

Because pricing and reimbursement remain national competencies, JCA does not directly harmonise European prices. It can, however, affect the timing and sequencing of national processes. Faster access to a common clinical assessment may allow some markets to progress more quickly into economic evaluation and negotiation.

That matters for International Reference Pricing. If national decisions become more synchronised, companies may have less flexibility to manage price visibility between early and later launches. Conversely, different national requirements could still produce significant variation in access timelines.

Implications for IRP and launch sequencing

Pricing teams should model JCA alongside launch sequence rather than treating it as a purely regulatory or evidence-generation change. Key questions include which markets may reach a visible price first, which markets reference one another, and whether a faster assessment pathway could accelerate an otherwise unexpected price cascade.

Economic models and payer research will also need to be ready earlier. The shared clinical assessment can become a common foundation, but the national value story still requires local epidemiology, costs, budget impact and policy context.

Preparation is cross-functional

The organisations best placed for the new environment will connect evidence generation, HTA, pricing, market access and IRP modelling from the outset. JCA is not a single European price mechanism, but it increases the interdependence of decisions across markets — exactly the kind of environment in which integrated scenario planning becomes most valuable.

This article reflects the market and policy context at the date of publication.

Further reading

• European Commission — Joint Clinical Assessments